What’s happening in health: July 28, 2024
Silvi Shah, MD, associate professor, discusses her latest research on home hemodialysis
A health segment on Local 12 News highlighted the research findings of Silvi Shah, MD, associate professor in the UC College of Medicine.
Shah found that dialysis patients using a more traditional home hemodialysis procedure have lower incidence of cardiovascular disease than patients using a less invasive peritoneal catheter for dialysis.
Shah’s work, published in Kidney360, an open access journal of the American Society of Nephrology, found that patients on home hemodialysis had a 42% lower risk of stroke, 17% lower risk of acute coronary syndrome, 22% lower risk of cardiovascular death and 8% lower risk of death.
Her study is based on the medical outcomes of 68,645 individuals on dialysis recorded in the United States Renal Data System between Jan. 1, 2005, and Dec. 31, 2018.
Listen to the segment featuring Dr. Shah on Local 12 News online. (Her interview starts at 30:23 and continues until 37:30).
Dr. Shah also did an interview on her research with Spectrum News.
Learn more about Dr. Shah’s research online.
Featured top image of a dialysis machine courtesy of Istock.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.